Education in the Use of Biomarkers in Diabetes (C-EUBD)

Membership

Terms of reference

1. To maintain and further develop the network of reference laboratories for the measurement of HbA_1c (through collaboration with C-TLM)
2. To work in partnership with WHO and IDF to continue to promote the reporting of HbA_1c in line with the consensus statement
3. To work in partnership with WHO and IDF to facilitate the development and implementation of international guidelines for the use of HbA_1c in the diagnosis of diabetes
4. To work with IFCC Corporate Members to develop a consensus position on the information to be included in the Instructions for Use (IFU) as it relates to the clinical use of HbA_1c methods
5. Develop quality targets for the measurement of HbA_1c and other biomarkers, and on the basis of these targets, and in conjunction with professional bodies, advise on the use of biomarkers for monitoring, diagnosis and screening of diabetes and glucose intolerance.
6. To work with WHO and TF-POCT to recommend best practice in the use of POCT methods for the measurement of HbA_1c
7. To evaluate the clinical value of emerging biomarkers (e.g. glycated albumin) for the management of patients with diabetes and to establish whether there is a case for method harmonisation of effective new biomarkers
8. To evaluate the emerging importance of post translational modification derived products (PTMDPs), and especially Advanced Glycation End-Products (AGEs), and work with Professional bodies on the best way of developing these for use in diabetes.
9. To monitor the literature and advise on best practice in relation to laboratory aspects of diabetes.

List of Corresponding Members, nominated by National Societies

List of Corresponding Members, nominated by Corporate Members

Committee Chair's contact

Prof. Garry JOHN
Consultant Clinical Biochemist
and Head of Clinical Biochemistry
Norfolk and Norwich University Hospital
UK
Tel: +44 (0) 1603 286 933